Loading clinical trials...
Loading clinical trials...
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma
Conditions
Interventions
Lenvatinib
Pembrolizumab
+1 more
Locations
1
United States
University of Miami
Miami, Florida, United States
Start Date
April 15, 2023
Primary Completion Date
April 15, 2027
Completion Date
April 15, 2030
Last Updated
February 24, 2026
NCT04704661
NCT06349642
NCT06502743
NCT03586661
NCT05192850
NCT05523440
Lead Sponsor
Aaron Wolfson
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions